{"id":"NCT03510715","sponsor":"Sanofi","briefTitle":"An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia","officialTitle":"An Open-Label Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-08-31","primaryCompletion":"2020-02-17","completion":"2020-02-17","firstPosted":"2018-04-27","resultsPosted":"2020-12-29","lastUpdate":"2020-12-29"},"enrollment":18,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hypercholesterolemia"],"interventions":[{"type":"DRUG","name":"Alirocumab SAR236553 (REGN727)","otherNames":[]},{"type":"DRUG","name":"Atorvastatin","otherNames":[]},{"type":"DRUG","name":"Simvastatin","otherNames":[]},{"type":"DRUG","name":"Fluvastatin","otherNames":[]},{"type":"DRUG","name":"Pravastatin","otherNames":[]},{"type":"DRUG","name":"Lovastatin","otherNames":[]},{"type":"DRUG","name":"Rosuvastatin","otherNames":[]},{"type":"DRUG","name":"Ezetimibe","otherNames":[]},{"type":"DRUG","name":"Cholestyramine","otherNames":[]},{"type":"DRUG","name":"Nicotinic acid","otherNames":[]},{"type":"DRUG","name":"Fenofibrate","otherNames":[]},{"type":"DRUG","name":"Omega-3 fatty acids","otherNames":[]}],"arms":[{"label":"Alirocumab","type":"EXPERIMENTAL"}],"summary":"Primary Objective:\n\nTo evaluate the efficacy of alirocumab (75 or 150 milligrams \\[mg\\] depending on body weight \\[BW\\]), administered every 2 weeks (Q2W), on low-density lipoprotein cholesterol (LDL-C) levels at Week 12 of treatment in children and adolescents with homozygous familial hypercholesterolemia (hoFH) of 8 to 17 years of age on top of background treatments.\n\nSecondary Objectives:\n\n* To evaluate the efficacy of alirocumab after 24 and 48 weeks of treatment on LDL-C levels.\n* To evaluate the effects of alirocumab on other lipid parameters (eg, apolipoprotein B \\[Apo B\\], non-high density lipoprotein cholesterol \\[non-HDL-C\\], total cholesterol \\[Total-C\\], high density lipoprotein cholesterol \\[HDL-C\\], lipoprotein a \\[Lp (a)\\], triglycerides \\[TG\\], apolipoprotein A-1 \\[Apo A-1\\] levels) after 12, 24, and 48 weeks of treatment.\n* To evaluate the safety and tolerability of alirocumab up to 48 weeks of treatment.","primaryOutcome":{"measure":"Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12: Intent-to-Treat (ITT) Analysis","timeFrame":"Baseline to Week 12","effectByArm":[{"arm":"Alirocumab","deltaMin":-4.1,"sd":9}],"pValues":[]},"eligibility":{"minAge":"8 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":11},"locations":{"siteCount":10,"countries":["Brazil","Canada","Denmark","Mexico","Netherlands","Russia","Slovenia","Spain","Taiwan","Turkey (TÃ¼rkiye)"]},"refs":{"pmids":["36325897"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":9},"commonTop":["Aortic Valve Incompetence","Nasopharyngitis","Headache","Influenza","Cough"]}}